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Abstract 
Malignant tumors of the nasal cavity are rare. We report 
the case of an elderly woman who consulted us with a 4-
year history of progressive nasal obstruction, occasional 
epistaxis, facial pain, and watering of the eyes. A diagnosis 
of olfactory neuroblastoma was established by histopathol-
ogy and conﬁrmed by immunohistochemistry. On staging, 
the mass was classiﬁed as a Kadish stage B tumor. The 
mass was excised via a lateral rhinotomy approach, and 
the tumor was peeled away completely from the cribriform 
plate with endoscopes. The patient underwent postopera-
tive radiation, and she was free of recurrence at follow-up 
15 months later. 
Introduction 
Malignant tumors of the nasal cavity are rare. Olfactory 
neuroblastomas (esthesioneuroblastomas) account for only 
6% of these neoplasms.1 Fewer than 1,000 cases have 
been reported in the literature since this tumor was ﬁrst 
described more than 75 years ago.2 These lesions can be 
easily missed because the presenting symptoms mimic those 
of benign tumors of the nose. They are often discovered 
incidentally during septoplasty or polypectomy.3 Because 
olfactory neuroblastomas are so uncommon, few data exist 
with respect to optimum management strategies, although 
diagnostic and treatment modalities have improved over the 
past 2 decades.3-5 Treatment recommendations range from 
a minimally invasive approach6 to craniofacial resection 
combined with radiotherapy.7 
In this article, we report a new case of olfactory neu-
roblastoma. 
Case report 
A 67-year-old woman consulted us with a 4-year history 
of progressive nasal obstruction, occasional epistaxis, 
facial pain, and watering of the eyes. On rhinoscopy, a 
polypoid mass was seen in the roof of her nose; the mass 
was not attached to the septum or lateral wall. Her vision 
in both eyes was normal, and her eye movements were 
unrestricted. Findings on the remainder of the head and 
neck examination were unremarkable. The patient had un-
dergone two surgical procedures elsewhere––3 and 1 years 
prior to presentation––during which intranasal excision of 
the mass had been attempted. These operations ultimately 
failed because of an incomplete removal of the mass and 
a lack of postoperative radiotherapy. 
We performed an intranasal biopsy with local anes-
thesia, which was completed with minimal bleeding. On 
histopathologic analysis, the tumor was identiﬁed as an 
olfactory neuroblastoma (ﬁgure 1, A). This ﬁnding was 
conﬁrmed by immunohistochemistry, which was positive 
for chromogranin, synaptophysin, neuron-speciﬁc enolase, 
and neuroﬁlament (ﬁgure 1, B). Computed tomography 
(CT) conﬁrmed that the tumor arose from the cribriform 
area; no intracranial extension was seen (ﬁgure 2, A). The 
ipsilateral anterior and postethmoid cells were involved, but 
the maxillary and sphenoid sinuses were free of tumor. The 
mass was removed via a lateral rhinotomy approach, and 
the tumor was peeled away completely from the cribriform 
plate with endoscopes. 
Two weeks after surgery, the patient received 6,000 cGy 
of radiation in 30 fractions. At follow-up 15 months later, 
she was free of recurrence (ﬁgure 2, B). 
Discussion 
Olfactory neuroblastomas arise from olfactory neuroepithe-
lium, which extends from the roof of the nose to the area of 
the superior turbinates and a portion of the nasal septum.7 
From there, they can readily extend into the cribriform 
plate of the ethmoid sinus. Most of the cases described in 
the literature involved adults, but 1 case has been reported 
in a child as young as 2 years of age.8 
Symptoms. The most common symptoms of olfactory 
neuroblastoma are nasal obstruction, epistaxis, and head-
ache (patients with extensive tumors may have orbital 
symptoms such as proptosis and excessive lacrimation).9 
Because most of these symptoms are similar to those of 
benign nasal disease, olfactory neuroblastoma is often 
Volume 84, Number 3 151
OLFACTORY NEUROBLASTOMA: A CASE REPORT AND REVIEW OF THE LITERATURE
missed during its early stages and not diagnosed until it 
has reached an advanced stage. 
Investigation. High-resolution CT and magnetic reso-
nance imaging can be used as complementary investigations 
to precisely delineate the extent of the tumor and to deﬁne 
the involvement of the cribriform plate, anterior cranial 
fossa, and retromaxillary space. Endoscopic examination 
is essential for evaluating the extent of the tumor and for 
obtaining a biopsy specimen. 
Microscopic analysis. The typical histologic appearance 
of an olfactory neuroblastoma includes the presence of 
characteristic cells separated into nests or compartments 
by ﬁbrovascular septae, neuroﬁbrillary intercellular ma-
trices, and rosette formations. The histologic diagnosis 
is often confounded by the various arrangements of cells 
packed in sheets and by an architecture that is similar to 
many neurogenic tumors. Immunohistochemistry, how-
ever, can lead to a deﬁnitive 
diagnosis; this tumor is positive 
for neuroendocrine markers such 
as chromogranin, synaptophysin, 
neuron-speciﬁc enolase, and pro-
tein gene product 9.5.10 
Staging. Because malignant 
lesions of the nasal cavity are 
so rare and because many dif-
ferent histologic types of tumors 
abound, no approved classiﬁca-
tion and staging system has been 
universally accepted. 
• The Hyams classiﬁcation 
(grades I through IV) is based 
on histologic differentiation; the 
grade IV designation is used to 
describe undifferentiated sinona-
sal carcinomas.11 
• More well accepted is the Kadish classiﬁcation system 
(stages A through C), which is based on the clinical spread 
of the tumor; stage A tumors are conﬁned to the nasal 
cavity, stage B lesions involve the sinuses, and stage C 
masses involve the middle cranial fossa and the retrobulbar 
orbit.12 Reservations about the Kadish system are based 
on the premise that there are minimal differences in the 
biologic behavior of stage A, B, and C tumors. Nevertheless, 
tumors in each of these classiﬁcations behave differently 
with respect to progression and metastasis and, therefore, 
survival patterns are different. 
• Biller et al introduced yet another classiﬁcation 
system, which takes into account the size of the primary 
tumor and the presence or absence of regional and distant 
metastasis.13 
Treatment. Surgical resection is the clear treatment of 
choice, but opinions vary as to its extent. Biller et al rec-
Figure 1. A: Histopathology demonstrates compact nests of uniform small cells with round basophilic nuclei and scant cytoplasm 
(H&E, original magniﬁcation ×20). B: The histopathology ﬁndings are conﬁrmed on immunohistochemistry, which is positive for 
chromogranin, synaptophysin, neuron-speciﬁc enolase, and neuroﬁlament. 
A B
Figure 2. A: Preoperative CT shows the tumor in the cribriform area. B: At follow-up 15 
months postoperatively, no sign of recurrence is evident. 
A B
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ommended craniofacial resection of all tumors, regardless 
of whether they invade the anterior cranial fossa or are 
conﬁned to the nasal roof.13 They advocated resection of 
the dura over the cribriform plate, the olfactory bulb, the 
entire ethmoid labyrinth, and the anterior and posterior 
walls of the frontal sinus. 
Preoperative irradiation appears to have no beneﬁcial 
effect. Postoperatively, some authors have recommended 
radiotherapy only for advanced tumors, while others have 
suggested that it should be administered to all patients 
regardless of tumor stage.14 As of now, craniofacial resec-
tion combined with radiotherapy is considered the gold 
standard in the management of these tumors.15 
Radical surgery of early lesions (Kadish stages A and 
B) is not performed at all centers. The results of transnasal 
endoscopic resection followed by radiation have been re-
ported to be comparable to those of craniofacial resection.15 
The pursuit of minimally invasive techniques has also led 
to the use of endoscopic resection of the tumor combined 
with stereotactic irradiation of the frontal skull base with a 
gamma-ray knife.6 This approach obviates the need for skin 
incisions and midface degloving and avoids the morbidity 
associated with conventional radiation therapy (e.g., optic 
neuropathy or retinopathy). Neck dissection is indicated 
only in the presence of nodes; elective dissection appears 
to be unnecessary. 
The role of induction chemotherapy or concurrent 
chemoradiation therapy has not been deﬁned. We know 
that olfactory neuroblastoma is chemosensitive and re-
sponsive to platinum-based agents,16,17 but chemotherapy 
is currently reserved for unresectable or recurrent tumors 
and for metastases. 
Metastasis. Olfactory neuroblastomas have the potential 
to spread regionally. Neck metastasis can occur early in 
the disease or many years later. Rinaldo et al reviewed 320 
cases at 15 centers and found that the incidence of both 
synchronous and metachronous neck metastases varied 
greatly, ranging from 5 to 100% (mean: 23.4%).10 As is true 
for most head and neck cancers, cervical lymphadenopathy 
augurs poorly and increases the risk of distant metastasis, 
most often to bones.18 
Recurrence. Despite aggressive therapy, recurrence can 
develop soon after treatment or even several years later. 
Researchers at the Mayo Clinic reported that 42% of local 
recurrences developed within 5 years postoperatively and 
that 1 case recurred as late as 10 years after surgery.19 In 
a review of 40 patients, Eden et al reported a recurrence 
rate of 55%; two-thirds of these patients had locoregional 
disease, and 39% of them developed recurrences within 
5 years of combined-modality (surgery plus radiation) 
treatment.20 Finally, researchers at the University of Iowa 
reported 5- and 10-year actuarial disease-free survival rates 
of 56 and 42%, respectively.4 
In conclusion, olfactory neuroblastoma requires ag-
gressive surgical resection and radiation therapy. Pa-
tients must be followed carefully with the understanding 
that locoregional recurrences are common and may arise 
several years after treatment. The prognosis for long-term 
survival is poor. 
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